Physician profile
Sharon Craft
NPI 1760693089
$8,249.81
in general payments reported to CMS, 2019-2025
22 companies · $2,119 in 2025
The $2,119 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $552 · 2022: $920 · 2023: $2,150 · 2024: $2,509 · 2025: $2,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,241 · Travel and Lodging: $527 · Education: $10.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,240.71 |
| Travel and Lodging | $526.98 |
| Education | $10.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,710.64 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,048.07 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $949.48 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neuronetics, INC. | $895.70 | 2023 | Neurostar Tms Therapy System |
| Janssen Pharmaceuticals, INC | $879.07 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Alkermes, INC. | $694.96 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $516.09 | 2021-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $291.09 | 2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $284.81 | 2024-2025 | Cobenfy |
| Corium, LLC | $187.56 | 2022-2023 | Azstarys, Azstarys |
| Sunovion Pharmaceuticals INC. | $170.49 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $154.56 | 2024-2025 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $149.22 | 2024 | Uzedy |
| Lundbeck LLC | $87.87 | 2024-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $59.14 | 2022-2023 | Quviviq |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $49.13 | 2024-2025 | Loreev Xr |
| Neos Therapeutics, LP | $32.46 | 2024 | Adzenys Xr-Odt |
| Collegium Pharmaceutical, INC. | $22.69 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $22.58 | 2023 | Trintellix |
| Noven Therapeutics, LLC | $18.94 | 2024 | Xelstrym, Secuado |
| Vanda Pharmaceuticals INC. | $16.55 | 2025 | Fanapt |
| Sumitomo Pharma America, INC. | $8.71 | 2023 | Latuda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Craft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.